Drug Trial Radar · NCT04297683
HEALEY ALS Platform Trial - Master Protocol
Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,500
Planned (sponsor's estimate)
Start
Jun 14, 2020
Primary completion
Jul 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Merit E. Cudkowicz, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Massachusetts General Hospital
- First posted
- Mar 5, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
ZilucoplanDrug
Drug: Zilucoplan Administration: Subcutaneous injection Dose: Minimum of .0.22 mg/kg daily to a maximum dose of 0.42 mg/kg daily, dependent on weight
VerdiperstatDrug
Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily
CNM-Au8Drug
Drug: CNM-Au8 Administration: Oral Dose: 30 mg or 60 mg daily
PridopidineDrug
Drug: Pridopidine Administration: Oral Dose: 45mg twice daily
SLS-005 TrehaloseDrug
Drug: SLS-005 Trehalose Administration: Infusion Dose: 0.75 g/kg weekly
ABBV-CLS-7262Drug
Drug: ABBV-CLS-7162 Administration: Oral Dose: Dose 1 or Dose 2
DNL343Drug
Drug: DNL343 Administration: Oral Dose: Once per day
NUZ-001Drug
Drug: NUZ-001. Administration: Oral. Dose: Once per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease ProgressionTime frame: 36 Weeks
Locations
81 sites in 1 country. Site status is shown where the registry gives one.
Barrow Neurological Institute
Phoenix, Arizona
Mayo Clinic Scottsdale
Scottsdale, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
UC San Diego
La Jolla, California
Loma Linda University Health
Loma Linda, California
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
University of Southern California
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
University of California, Irvine
Orange, California
Forbes Norris MDA/ALS Research Center, California Pacific Medical Center
San Francisco, California
University of California, San Francisco
San Francisco, California
University of Colorado
Aurora, Colorado
Hospital for Special Care
New Britain, Connecticut
Yale University
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
George Washington University
Washington D.C., District of Columbia
Nova Southeastern University
Davie, Florida
University of Florida
Gainesville, Florida
Mayo Clinic Florida
Jacksonville, Florida
University of Miami
Miami, Florida
University of South Florida
Tampa, Florida
Augusta University
Augusta, Georgia
Saint Alphonsus Regional Medical Center
Boise, Idaho
Northwestern University
Chicago, Illinois
University of Chicago
Chicago, Illinois
Indiana University Health
Indianapolis, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Fairway, Kansas
University of Kentucky
Lexington, Kentucky
Ochsner Health System
New Orleans, Louisiana
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Lahey Hospital and Medical Center
Burlington, Massachusetts
University of Massachusetts Medical School
North Worcester, Massachusetts
University of Michigan
Ann Arbor, Michigan
Henry Ford Health System
Detroit, Michigan
Spectrum Health/Corewell Health
Grand Rapids, Michigan
Essentia Health
Duluth, Minnesota
University of Minnesota Medical School
Minneapolis, Minnesota
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.